|
BIOLOGIC SAFETY RESEARCH INC. (BSR) JOINS PRELABS, L.L.C. TO FORM AN EXPANDED PRECLINICAL TOXICOLOGY CONTRACT RESEARCH ORGANIZATION. Oak Park, IL, October 1, 2008 - Biologic Safety Research Inc. (BSR) announced today it is joining PreLabs, LLC to expand its operations. The existing BSR management team will integrate into the PreLabs organization and continue to actively guide the future of the expanded contract laboratory. Additionally, PreLabs has appointed Boris Predovich to serve as President/CEO and Philippe Baneux DVM as Chief Scientific Officer for the newly expanded company. Biologic Safety Research has been providing toxicology and preclinical services since 1988. "Market demand has created an exciting opportunity for us to expand our business." said Robert Locke, BSR President. "Transitioning BSR into PreLabs will leverage our existing scientific and operational expertise while adding the CRO and pharmaceutical management expertise that Boris Predovich and Philippe Baneux bring with their 20 plus years at Covance and Pfizer respectively." PreLabs/BSR provides discovery, preclinical and GLP testing in our state-of-the-art, AAALAC International-accredited vivaria. "We will continue the long-established tradition of understanding our clients' requirements and bringing academic and industry leaders together to collaborate and develop innovative strategies that facilitate globally competitive, value-driven outsourcing solutions." said Boris Predovich, PreLabs President/CEO. For more information please contact us at 1.708.613.6000 or visit www.PreLabs.com. |
|
BIOLOGIC SAFETY RESEARCH INC. (BSR) JOINS PRELABS, L.L.C. TO FORM AN EXPANDED PRECLINICAL TOXICOLOGY CONTRACT RESEARCH ORGANIZATION.
Oak Park, IL, October 1, 2008 - Biologic Safety Research Inc. (BSR) announced today it is joining PreLabs, LLC to expand its operations. The existing BSR management team will integrate into the PreLabs organization and continue to actively guide the future of the expanded contract laboratory. Additionally, PreLabs has appointed Boris Predovich to serve as President/CEO and Philippe Baneux DVM as Chief Scientific Officer for the newly expanded company. Biologic Safety Research has been providing toxicology and preclinical services since 1988. "Market demand has created an exciting opportunity for us to expand our business." said Robert Locke, BSR President. "Transitioning BSR into PreLabs will leverage our existing scientific and operational expertise while adding the CRO and pharmaceutical management expertise that Boris Predovich and Philippe Baneux bring with their 20 plus years at Covance and Pfizer respectively." PreLabs/BSR provides discovery, preclinical and GLP testing in our state-of-the-art, AAALAC International-accredited vivaria. "We will continue the long-established tradition of understanding our clients' requirements and bringing academic and industry leaders together to collaborate and develop innovative strategies that facilitate globally competitive, value-driven outsourcing solutions." said Boris Predovich, PreLabs President/CEO. For more information please contact us at 1.708.613.6000 or visit www.PreLabs.com. |
![]() Press Release - June 30, 2011PRELABS AND THREE SPRINGS SCIENTIFIC FORM AN EXPANDED NHP DIVISION - PrímGen
Oak Park, IL, June 30, 2011 - PreLabs announced today that it has been joined by Jim Sears of Three Springs Scientific (TSS) to support the expansion of PrímGen, a nonhuman primate (NHP) division of PreLabs.
PrímGen will be led by Jim Sears, Founder and President of Three Springs Scientific. "Over the last 20 years, TSS has built its reputation on providing timely customer support through its commitment to understanding the client requirements and delivering on their expectations," said Jim Sears.
The expanded division is dedicated to supporting the global preclinical NHP programs by providing: importation, quarantine, distribution, genetics, staging, logistics, tissue and bio-products to the Pharma, CRO, Academic, and Governmental institutions. "We have developed an innovative NHP solution which leverages genetics, veterinary, and toxicology expertise along with the breeding, logistics and operational skills that are vital to optimizing quality standards while reducing usage and costs." said Boris Predovich, President & CEO of PreLabs.
PreLabs is an innovative preclinical contract support organization focused on facilitating creative
solutions performed in AAALAC International accredited facilities with OLAW assurances. TSS has been providing NHP services and support to the biomedical research community since 1989.
|
![]() Press Release - June 30, 2011PRELABS AND THREE SPRINGS SCIENTIFIC FORM AN EXPANDED NHP DIVISION - PrímGen
Oak Park, IL, June 30, 2011 - PreLabs announced today that it has been joined by Jim Sears of Three Springs Scientific (TSS) to support the expansion of PrímGen, a nonhuman primate (NHP) division of PreLabs.
PrímGen will be led by Jim Sears, Founder and President of Three Springs Scientific. "Over the last 20 years, TSS has built its reputation on providing timely customer support through its commitment to understanding the client requirements and delivering on their expectations," said Jim Sears.
The expanded division is dedicated to supporting the global preclinical NHP programs by providing: importation, quarantine, distribution, genetics, staging, logistics, tissue and bio-products to the Pharma, CRO, Academic, and Governmental institutions. "We have developed an innovative NHP solution which leverages genetics, veterinary, and toxicology expertise along with the breeding, logistics and operational skills that are vital to optimizing quality standards while reducing usage and costs." said Boris Predovich, President & CEO of PreLabs.
PreLabs is an innovative preclinical contract support organization focused on facilitating creative
solutions performed in AAALAC International accredited facilities with OLAW assurances. TSS has been providing NHP services and support to the biomedical research community since 1989.
|
|
PRELABS, LLC ANNOUNCES KENNETH DRAPER, PhD, DABT, AS SCIENTIFIC CONSULTANT Oak Park, IL, August 19, 2009 - PreLabs, LLC, a Chicago-based contract research organization, is pleased to announce the addition of Ken Draper, PhD, DABT, as Scientific Consultant. Dr. Draper has 25 years of experience in discovery and development of small molecule and biotechnology products. During his recent tenure at Charles River Laboratories and Sierra Biomedical, Inc., he amassed substantial experience in understanding the biology of nonhuman primates and their use for toxicology/safety assessments. His drug development expertise encompasses therapeutic modalities/biologics including monoclonal antibodies, vaccines, proteins/peptides, oligonucleotides (including siRNA), and various gene and cell therapy platforms. He has designed and/or managed 50 preclinical programs and has directed 300 toxicology studies in a variety of animal models. "Ken's expertise and background in virology and molecular genetics along with his extensive industry knowledge advances PreLabs' ability to serve its clients with enhanced efficiency", said Philippe Baneux, PreLabs Chief Scientific Officer. PreLabs provides contract outsourcing services focused on discovery, preclinical and GLP-compliant testing in state-of-the-art, AAALAC International-accredited vivaria. For more information please contact us at 1.708.613.6000 or visit www.PreLabs.com. |
|
PRELABS, LLC ANNOUNCES KENNETH DRAPER, PhD, DABT, AS SCIENTIFIC CONSULTANT Oak Park, IL, August 19, 2009 - PreLabs, LLC, a Chicago-based contract research organization, is pleased to announce the addition of Ken Draper, PhD, DABT, as Scientific Consultant. Dr. Draper has 25 years of experience in discovery and development of small molecule and biotechnology products. During his recent tenure at Charles River Laboratories and Sierra Biomedical, Inc., he amassed substantial experience in understanding the biology of nonhuman primates and their use for toxicology/safety assessments. His drug development expertise encompasses therapeutic modalities/biologics including monoclonal antibodies, vaccines, proteins/peptides, oligonucleotides (including siRNA), and various gene and cell therapy platforms. He has designed and/or managed 50 preclinical programs and has directed 300 toxicology studies in a variety of animal models. "Ken's expertise and background in virology and molecular genetics along with his extensive industry knowledge advances PreLabs' ability to serve its clients with enhanced efficiency", said Philippe Baneux, PreLabs Chief Scientific Officer. PreLabs provides contract outsourcing services focused on discovery, preclinical and GLP-compliant testing in state-of-the-art, AAALAC International-accredited vivaria. For more information please contact us at 1.708.613.6000 or visit www.PreLabs.com. |